Novocure Ltd Ord Sh (NVCR) Stock Price, Quote & News

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, p...

Industry: Medical Devices

Sector: Healthcare

Website: www.novocure.com

Address:

Neuhofstrasse 21, Baar, Switzerland

GJ_Rockabilt Apr. 27 at 1:26 PM

$NVCR SQUEEZABLE $NTLA Catalyst, TODAY! Phase III Results! https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-reports-positive-phase-110000601.html

0 · Reply

Czm514 Apr. 25 at 1:29 PM

$NVCR Could we see a follow up on this study in May? Whatever became of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device”

0 · Reply

kwcurtis Apr. 23 at 12:04 AM

$NVCR the amount of huge daily moves on this thing is quite something…

0 · Reply

scotofool Apr. 22 at 1:59 PM

$NVCR mates diplebee da drug over fakky tekk two score and long, no burnz and gapes inda bowlz,$NVCR proper trash, target 7

1 · Reply

Tdorsey1776 Apr. 22 at 1:49 PM

$NVCR Real world relevance......."The quality-of-life and pain-free survival data from PANOVA-3 are arguably as clinically important as the survival data. In a disease where suffering is often as much the enemy as survival itself, a therapy that extends the time before pain progresses deserves more attention than it has received."

0 · Reply

TriGuy8542 Apr. 21 at 9:31 PM

$NVCR saw a patient using NVCR this morning when I was gasin up in Sam’s.

0 · Reply

scotofool Apr. 20 at 2:49 PM

$NVCR wankers great company my arse ballyswog CEO, proper cock-up medusa, target 7

0 · Reply

4Reel Apr. 19 at 2:17 AM

$NVCR a big ER mon morning. Great company, heavily tute owned, good revenues. Def one of top watches monday to see the reaction to the ER

2 · Reply

GordonGecko_was_THE_MAN Apr. 17 at 8:45 PM

$NVCR https://panova-pdac-matteotti.tiiny.site/

1 · Reply

scotofool Apr. 17 at 1:34 PM

$NVCR piles of rubbish, CEO proper cock-up, no userdoccies fakky teks, target 7

1 · Reply

Novocure to Report First Quarter 2026 Financial Results

Mar 26, 2026, 11:19 AM EDT - 4 weeks ago

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

Mar 26, 2026, 7:00 AM EDT - 4 weeks ago

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Mar 10, 2026, 11:20 AM EDT - 7 weeks ago

NovoCure Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 7:00 AM EST - 2 months ago

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Feb 27, 2026, 4:30 PM EST - 2 months ago

Novocure to Participate in 2026 Leerink Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Feb 24, 2026, 7:00 AM EST - 2 months ago

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Feb 12, 2026, 6:53 AM EST - 2 months ago

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Feb 12, 2026, 6:15 AM EST - 2 months ago

What's Happening With NovoCure Stock?

Feb 11, 2026, 6:33 PM EST - 2 months ago

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

Feb 11, 2026, 5:54 PM EST - 2 months ago

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Jan 14, 2026, 12:45 PM EST - 3 months ago

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 3 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Dec 22, 2025, 7:00 AM EST - 4 months ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 5 months ago

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 5 months ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Nov 26, 2025, 7:00 AM EST - 5 months ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 19, 2025, 9:00 AM EST - 5 months ago

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 7:00 AM EST - 6 months ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Oct 30, 2025, 8:00 AM EDT - 6 months ago

NovoCure Earnings Call Transcript: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Novocure Reports Third Quarter 2025 Financial Results

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 7:00 AM EDT - 7 months ago

Novocure to Report Third Quarter 2025 Financial Results

Sep 29, 2025, 4:30 PM EDT - 7 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 10, 2025, 3:20 PM EDT - 8 months ago

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 2:00 PM EDT - 8 months ago

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 9:30 AM EDT - 8 months ago

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Novocure Announces Upcoming Investor Events

Aug 25, 2025, 7:00 AM EDT - 8 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 20, 2025, 7:00 AM EDT - 9 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Jul 28, 2025, 6:52 AM EDT - 9 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH

Jul 24, 2025, 8:00 AM EDT - 9 months ago

NovoCure Earnings Call Transcript: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 9 months ago

Novocure Reports Second Quarter 2025 Financial Results

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Novocure to Report Second Quarter 2025 Financial Results

Jun 4, 2025, 12:50 PM EDT - 11 months ago

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 2:05 PM EDT - 11 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

May 31, 2025, 8:01 PM EDT - 11 months ago

NovoCure Transcript: Study Result

May 31, 2025, 3:08 PM EDT - 11 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

May 31, 2025, 8:00 AM EDT - 11 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Apr 24, 2025, 12:39 PM EDT - 1 year ago

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q1 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 1 year ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 7:09 AM EDT - 1 year ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2025 Financial Results

Mar 11, 2025, 4:20 PM EDT - 1 year ago

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Jan 22, 2025, 4:00 AM EST - 1 year ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 15, 2025, 12:00 PM EST - 1 year ago

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 2, 2024, 10:12 AM EST - 1 year ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Dec 2, 2024, 7:17 AM EST - 1 year ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:02 AM EST - 1 year ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Dec 2, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q3 2024

Oct 30, 2024, 7:02 AM EDT - 1 year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results

Sep 4, 2024, 4:30 PM EDT - 1 year ago

NovoCure Transcript: 2024 Wells Fargo Healthcare Conference

Jul 25, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q2 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

NovoCure Earnings Call Transcript: Q1 2024

Mar 27, 2024, 8:00 AM EDT - 2 years ago

NovoCure Transcript: Study update

Feb 22, 2024, 8:00 AM EST - 2 years ago

NovoCure Earnings Call Transcript: Q4 2023

Jan 10, 2024, 10:30 AM EST - 2 years ago

NovoCure Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 29, 2023, 3:30 PM EST - 2 years ago

NovoCure Transcript: Piper Sandler 35th Annual Healthcare Conference

Oct 26, 2023, 8:00 AM EDT - 2 years ago

NovoCure Earnings Call Transcript: Q3 2023

Sep 13, 2023, 8:10 AM EDT - 2 years ago

NovoCure Transcript: Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 12:45 PM EDT - 2 years ago

NovoCure Transcript: Wells Fargo Securities Healthcare Conference 2023

Jul 27, 2023, 8:00 AM EDT - 2 years ago

NovoCure Earnings Call Transcript: Q2 2023

Jun 6, 2023, 3:00 PM EDT - 3 years ago

NovoCure Transcript: Study Update

May 4, 2023, 8:00 AM EDT - 3 years ago

NovoCure Earnings Call Transcript: Q1 2023

Feb 23, 2023, 8:00 AM EST - 3 years ago

NovoCure Earnings Call Transcript: Q4 2022

Oct 27, 2022, 8:00 AM EDT - 3 years ago

NovoCure Earnings Call Transcript: Q3 2022

Jul 28, 2022, 6:24 AM EDT - 4 years ago

NovoCure Earnings Call Transcript: Q2 2022

Apr 28, 2022, 6:37 AM EDT - 4 years ago

NovoCure Earnings Call Transcript: Q1 2022

Feb 24, 2022, 10:00 AM EST - 4 years ago

NovoCure Earnings Call Transcript: Q4 2021

Oct 27, 2021, 8:00 PM EDT - 4 years ago

NovoCure Earnings Call Transcript: Q3 2021

Jul 28, 2021, 8:00 PM EDT - 5 years ago

NovoCure Earnings Call Transcript: Q2 2021

Apr 29, 2021, 10:52 AM EDT - 5 years ago

NovoCure Earnings Call Transcript: Q1 2021

Feb 25, 2021, 8:00 AM EST - 5 years ago

NovoCure Earnings Call Transcript: Q4 2020

Nov 12, 2020, 7:00 AM EST - 5 years ago

NovoCure Transcript: R&D Day 2020

Oct 29, 2020, 8:00 AM EDT - 5 years ago

NovoCure Earnings Call Transcript: Q3 2020

Jul 30, 2020, 8:00 AM EDT - 6 years ago

NovoCure Earnings Call Transcript: Q2 2020

Apr 30, 2020, 8:00 AM EDT - 6 years ago

NovoCure Earnings Call Transcript: Q1 2020

GJ_Rockabilt Apr. 27 at 1:26 PM

$NVCR SQUEEZABLE $NTLA Catalyst, TODAY! Phase III Results! https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-reports-positive-phase-110000601.html

0 · Reply

Czm514 Apr. 25 at 1:29 PM

0 · Reply

kwcurtis Apr. 23 at 12:04 AM

$NVCR the amount of huge daily moves on this thing is quite something…

0 · Reply

scotofool Apr. 22 at 1:59 PM

$NVCR mates diplebee da drug over fakky tekk two score and long, no burnz and gapes inda bowlz,$NVCR proper trash, target 7

1 · Reply

Tdorsey1776 Apr. 22 at 1:49 PM

0 · Reply

TriGuy8542 Apr. 21 at 9:31 PM

$NVCR saw a patient using NVCR this morning when I was gasin up in Sam’s.

0 · Reply

scotofool Apr. 20 at 2:49 PM

$NVCR wankers great company my arse ballyswog CEO, proper cock-up medusa, target 7

0 · Reply

4Reel Apr. 19 at 2:17 AM

$NVCR a big ER mon morning. Great company, heavily tute owned, good revenues. Def one of top watches monday to see the reaction to the ER

2 · Reply

GordonGecko_was_THE_MAN Apr. 17 at 8:45 PM

$NVCR https://panova-pdac-matteotti.tiiny.site/

1 · Reply

scotofool Apr. 17 at 1:34 PM

$NVCR piles of rubbish, CEO proper cock-up, no userdoccies fakky teks, target 7

1 · Reply

BB_88_ Apr. 16 at 9:53 PM

$NVCR nice run before earnings wish i kept my 10s

0 · Reply

Tdorsey1776 Apr. 16 at 3:41 PM

$NVCR Swimming upstream aginst the XBI current, good to see the relative strength. Shorts beginning to cover a bit perhaps.

3 · Reply

azerd Apr. 15 at 9:42 PM

$NVCR It's not clear to me how $RVMD 's recent pancreatic cancer breakthrough will affect Novocures launch. Their results were good enough that I think that many of the doctors that want best for their patients would want to use it first line even if the trials for first line have not been formally done yet. And they should be allowed to but insurance companies aren't really known for their humanitarism and I think many will avoid paying for the treatment until a more formal 1st line approval is granted? Would the doctors treating patients with daraxonrasib prescribe TTF alongside it? I'm guessing at least half wouldn't due to TTF skepticism and no direct trials of the combo giving them a reason not to. But I think the most likely outcome in the short-medium term is daraxonrasib stays in the 2nd line for a while, also because it's side effect profile is not benign.

1 · Reply

Czm514 Apr. 13 at 2:59 PM

$NVCR 3 approved indications and the stock is left for dead. Paging Dr Howard, Dr Fine, Dr Howard…..

3 · Reply

Stonkapedia Apr. 10 at 10:58 AM

$NVCR

1 · Reply

buylowandwait Apr. 9 at 4:23 PM

$NVCR It is quite amazing that the tentative cease fire triggered broad market upswing, but NVCR continues stuck in bottom. Why was it even remotely possible that it was 200/share a few years back, there was only one indication back then, now 3 approved indications, talking about lost confidence in this company !

1 · Reply

Stonkapedia Apr. 7 at 11:44 PM

$NVCR still a POS 😂 💩

0 · Reply

scotofool Apr. 7 at 3:29 PM

$NVCR mates this trash proper cock-up, target 7

1 · Reply

Czm514 Apr. 6 at 3:25 PM

$NVCR Whatever came of this press release back in August 2025? “Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device” Doyle and co are desperately searching for a combo partner to bring relevance and market acceptance to Optune. Too afraid to piss off Roche and Merk?

1 · Reply

BB_88_ Apr. 2 at 5:52 PM

$NVCR in 3k shares

1 · Reply

BB_88_ Mar. 31 at 2:38 PM

$NVCR in 3k shares 10.35

1 · Reply

Do_Your_Research Mar. 30 at 7:22 PM

$NVCR we’re gonna be setting new 52 week lows soon

2 · Reply

Market Cap	1.44B
Revenue (ttm)	655.35M
Net Income (ttm)	-136.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.79%
Debt to Equity Ratio	0.70

Volume	728,709
Avg Vol	1,546,628
Day's Range	N/A - N/A
Shares Out	115.82M
Stochastic %K	4%
Beta	0.82
Analysts	Strong Sell
Price Target	$25.07